Literature DB >> 21563210

Minimum important difference for validated instruments in women with urge incontinence.

Keisha Y Dyer1, Yan Xu, Linda Brubaker, Ingrid Nygaard, Alayne Markland, David Rahn, Toby C Chai, Ann Stoddard, Emily Lukacz.   

Abstract

AIMS: Minimum important difference (MID) estimates the minimum degree of change in an instrument's score that correlates with subjective sense of improvement. The aim of this study was to estimate the MID for the Urogenital Distress Inventory (UDI), Incontinence Impact Questionnaire (IIQ) and Overactive Bladder Questionnaire (OAB-q) using anchor and distribution-based approaches in patients with urge-predominant incontinence and whether MID changes over time.
METHODS: This was a sub-analysis of a multi-center trial of 307 women with pure urge (11) or urge-predominant (296) incontinence who completed condition-specific instruments 10 weeks and 8 months after randomization to anticholinergic medication with or without behavioral therapy. We applied anchor-based methods only when the Kendall's rank correlations between the anchors (Global Perception of Improvement (GPI), Patient Satisfaction Questionnaire (PSQ), and incontinence episodes) and the incontinence instruments (UDI, UDI irritative subscale, IIQ, and OAB-q subscales) were ≥ 0.3. We applied three distribution-based methods to all instruments: effect sizes of ± 0.2 SD (small) and ± 0.5 SD (medium), and standard error of measurement of ± 1. Analyses were performed at both time points.
RESULTS: Anchor-based MIDs for the UDI ranged from -35 to -45 and -15 to -25 for the irritative subscale distribution-based methods MIDs for UDI and IIQ ranged between -10 to -25 and -19 to -49, respectively, reflective of a reduction in bother and symptom severity (SS). OAB-q subscale MIDs ranged from +5 to +12, denoting improved quality of life (HRQL) and -13 to -25, consistent with a reduction in SS.
CONCLUSIONS: The MID in women with urge-predominant UI for the UDI and UDI irritative are -35 and -15. Our findings are consistent with previously reported MIDs for the OAB-q subscales. Distribution-based method MIDs are lower values than anchor-based values. The MID did not typically change over the time.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21563210      PMCID: PMC5373473          DOI: 10.1002/nau.21028

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  18 in total

1.  Using the standard error of measurement to identify important changes on the Asthma Quality of Life Questionnaire.

Authors:  Kathleen W Wyrwich; William M Tierney; Fredric D Wolinsky
Journal:  Qual Life Res       Date:  2002-02       Impact factor: 4.147

Review 2.  Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes.

Authors:  Dennis Revicki; Ron D Hays; David Cella; Jeff Sloan
Journal:  J Clin Epidemiol       Date:  2007-08-03       Impact factor: 6.437

3.  Determining the importance of change in the overactive bladder questionnaire.

Authors:  Karin S Coyne; Louis S Matza; Christine L Thompson; Zoe S Kopp; Vikram Khullar
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450

4.  Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ).

Authors:  Louis S Matza; Christine L Thompson; Joel Krasnow; Jessica Brewster-Jordan; Teresa Zyczynski; Karin S Coyne
Journal:  Neurourol Urodyn       Date:  2005       Impact factor: 2.696

5.  Global ratings of patient satisfaction and perceptions of improvement with treatment for urinary incontinence: validation of three global patient ratings.

Authors:  Kathryn L Burgio; Patricia S Goode; Holly E Richter; Julie L Locher; David L Roth
Journal:  Neurourol Urodyn       Date:  2006       Impact factor: 2.696

6.  Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.

Authors:  K Coyne; D Revicki; T Hunt; R Corey; W Stewart; J Bentkover; H Kurth; P Abrams
Journal:  Qual Life Res       Date:  2002-09       Impact factor: 4.147

7.  Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial.

Authors:  Kathryn L Burgio; Stephen R Kraus; Shawn Menefee; Diane Borello-France; Marlene Corton; Harry W Johnson; Veronica Mallett; Peggy Norton; Mary P FitzGerald; Kimberly J Dandreo; Holly E Richter; Thomas Rozanski; Michael Albo; Halina M Zyczynski; Gary E Lemack; Toby C Chai; Salil Khandwala; Jan Baker; Linda Brubaker; Anne M Stoddard; Patricia S Goode; Betsy Nielsen-Omeis; Charles W Nager; Kimberly Kenton; Sharon L Tennstedt; John W Kusek; T Debuene Chang; Leroy M Nyberg; William Steers
Journal:  Ann Intern Med       Date:  2008-08-05       Impact factor: 25.391

8.  Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group.

Authors:  S A Shumaker; J F Wyman; J S Uebersax; D McClish; J A Fantl
Journal:  Qual Life Res       Date:  1994-10       Impact factor: 4.147

9.  Costs of urinary incontinence and overactive bladder in the United States: a comparative study.

Authors:  Teh-Wei Hu; Todd H Wagner; Judith D Bentkover; Kristi Leblanc; Steve Z Zhou; Timothy Hunt
Journal:  Urology       Date:  2004-03       Impact factor: 2.649

10.  Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo.

Authors:  Philip E V Van Kerrebroeck; Con J Kelleher; Karin S Coyne; Zoe Kopp; Marina Brodsky; Joseph T Wang
Journal:  Health Qual Life Outcomes       Date:  2009-02-18       Impact factor: 3.186

View more
  16 in total

1.  Cystodistension versus cystoscopy in patients with refractory detrusor overactivity: a randomized controlled trial.

Authors:  Aswini Balachandran; Natasha Curtiss; Maya Basu; Jonathan Duckett
Journal:  Int Urogynecol J       Date:  2017-04-24       Impact factor: 2.894

2.  Life Space Assessment in Older Women Undergoing Non-Surgical Treatment for Urinary Incontinence.

Authors:  Thomas L Wheeler; Jana D Illston; Alayne D Markland; Patricia S Goode; Holly E Richter
Journal:  Open J Obstet Gynecol       Date:  2014-10

3.  Outcomes of midurethral sling procedures in women with mixed urinary incontinence.

Authors:  Jonathan L Gleason; Alison M Parden; Victoria Jauk; Alicia Ballard; Vivian Sung; Holly E Richter
Journal:  Int Urogynecol J       Date:  2015-01-10       Impact factor: 2.894

4.  Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.

Authors:  Anthony G Visco; Linda Brubaker; Holly E Richter; Ingrid Nygaard; Marie Fidela R Paraiso; Shawn A Menefee; Joseph Schaffer; Jerry Lowder; Salil Khandwala; Larry Sirls; Cathie Spino; Tracy L Nolen; Dennis Wallace; Susan F Meikle
Journal:  N Engl J Med       Date:  2012-10-04       Impact factor: 91.245

5.  Does concomitant anterior/apical repair during midurethral sling improve the overactive bladder component of mixed incontinence?

Authors:  Alexis A Dieter; Autumn L Edenfield; Alison C Weidner; Pamela J Levin; Nazema Y Siddiqui
Journal:  Int Urogynecol J       Date:  2014-05-09       Impact factor: 2.894

6.  Methods for a multicenter randomized trial for mixed urinary incontinence: rationale and patient-centeredness of the ESTEEM trial.

Authors:  Vivian W Sung; Diane Borello-France; Gena Dunivan; Marie Gantz; Emily S Lukacz; Pamela Moalli; Diane K Newman; Holly E Richter; Beri Ridgeway; Ariana L Smith; Alison C Weidner; Susan Meikle
Journal:  Int Urogynecol J       Date:  2016-06-10       Impact factor: 2.894

7.  Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY).

Authors:  P Abrams; C Kelleher; D Staskin; R Kay; A Martan; I Mincik; D Newgreen; A Ridder; A Paireddy; R van Maanen
Journal:  World J Urol       Date:  2016-08-11       Impact factor: 4.226

8.  Effect of Behavioral and Pelvic Floor Muscle Therapy Combined With Surgery vs Surgery Alone on Incontinence Symptoms Among Women With Mixed Urinary Incontinence: The ESTEEM Randomized Clinical Trial.

Authors:  Vivian W Sung; Diane Borello-France; Diane K Newman; Holly E Richter; Emily S Lukacz; Pamela Moalli; Alison C Weidner; Ariana L Smith; Gena Dunivan; Beri Ridgeway; John N Nguyen; Donna Mazloomdoost; Benjamin Carper; Marie G Gantz
Journal:  JAMA       Date:  2019-09-17       Impact factor: 56.272

9.  The minimum important difference for the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form in women with stress urinary incontinence.

Authors:  Larry T Sirls; Sharon Tennstedt; Linda Brubaker; Hae-Young Kim; Ingrid Nygaard; David D Rahn; Jonathan Shepherd; Holly E Richter
Journal:  Neurourol Urodyn       Date:  2013-11-23       Impact factor: 2.696

10.  Cost-effectiveness of behavioral and pelvic floor muscle therapy combined with midurethral sling surgery vs surgery alone among women with mixed urinary incontinence: results of the Effects of Surgical Treatment Enhanced With Exercise for Mixed Urinary Incontinence randomized trial.

Authors:  Heidi S Harvie; Vivian W Sung; Simon J Neuwahl; Amanda A Honeycutt; Isuzu Meyer; Christopher J Chermansky; Shawn Menefee; Whitney K Hendrickson; Gena C Dunivan; Donna Mazloomdoost; Sarah J Bass; Marie G Gantz
Journal:  Am J Obstet Gynecol       Date:  2021-07-06       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.